Has the WHO Pandemic Agreement Just Codified a Two-Tiered Global Health Security System?

When the World Health Assembly adopted the historic WHO Pandemic Agreement in May 2025, it was heralded as a triumph of multilateralism—a promise that the catastrophic inequities of the COVID-19 era would never be repeated. But more than a year later, the treaty remains frozen in a bureaucratic stalemate, unable to enter into force.[2][4]

The core of the paralysis lies in a single, unfinished addendum: the Pathogen Access and Benefit-Sharing (PABS) annex. This mechanism was designed to be the engine of global equity, ensuring that when a new biological threat emerges, the countries that share the pathogen data are guaranteed a fair share of the resulting vaccines and therapeutics.[1]

However, negotiators missed a critical deadline in May 2026 to finalize the PABS annex, forcing the Intergovernmental Working Group to extend its mandate to 2027. Because the treaty's rules explicitly prohibit ratification until the annex is adopted, the entire global health security architecture is now in a holding pattern.[2]

This delay has exposed a fundamental ideological rift over how the world should manage biological crises. At the heart of the dispute is the fear that the Pandemic Agreement, in its current draft form, might inadvertently codify the very two-tiered health system it was meant to dismantle.[4]

The mechanics of the proposed PABS system highlight this tension. Under the current framework, declaring a pandemic emergency would activate mandatory obligations for pharmaceutical manufacturers who access pathogen data.

These obligations currently center on a 20% allocation rule: manufacturers would be required to donate 10% of their real-time production to the WHO and provide another 10% at affordable prices.[4]

While this guarantees a baseline of equitable distribution, it mathematically leaves 80% of all pandemic countermeasures to the open market. Critics argue that this structure legally ring-fences a two-tiered system, where high-income nations can use their financial leverage to buy up the vast majority of supplies through bilateral agreements, just as they did in 2020.[4]

The debate over how to govern this system has crystallized into two competing proposals. During the seventh round of negotiations in July 2026, African nations consolidated behind a "Federated Model" to ensure strict compliance.[1]

The Federated Model demands strict, legally binding contracts. It requires that any manufacturer seeking access to pathogen data must sign a Data Access Agreement with the host country and a benefit-sharing contract with the WHO, ensuring that equity is a non-negotiable prerequisite for research.[1]

In stark contrast, the European Union and its allies have proposed a "Hybrid Model." This approach envisions a mix of mandatory and voluntary measures, allowing pathogen materials to be shared through both a WHO-controlled system and alternative national processes based on mutually agreed terms.[1]

Proponents of the Hybrid Model argue that it prevents bureaucratic bottlenecks, ensuring that scientists have rapid, frictionless access to the genetic sequences necessary to develop life-saving vaccines. They warn that overly restrictive access conditions could slow down the global research and development response when days matter most.[1]

But for the Global South, the Hybrid Model looks like a loophole that dilutes access conditionalities and perpetuates the status quo. They argue that without ironclad, mandatory benefit-sharing, lower-income countries will once again serve as mere extraction sites for biological data, providing the raw materials for vaccines they ultimately cannot afford.[1][3]

The implications of this standoff extend far beyond the negotiating rooms in Geneva. The revised International Health Regulations recently introduced the concept of a Public Health Emergency of International Concern (PHEIC) that falls short of a full pandemic—such as the recent Ebola Bundibugyo outbreak—which would also trigger these PABS obligations.

This means the rules currently being debated will govern not just once-in-a-century pandemics, but the routine management of regional outbreaks. The failure to finalize the PABS annex leaves the world without a coordinated framework for these escalating threats.

Furthermore, the procedural dependency created by Article 31 of the agreement means that other vital components of the treaty—such as strengthening disease surveillance, safeguarding healthcare workforces, and implementing One Health initiatives—cannot legally enter into force.[2]

The Intergovernmental Working Group has scheduled further meetings for late 2026, with a firm target of presenting a finalized annex to the Eightieth World Health Assembly in May 2027.[2]

Until then, the promise of the WHO Pandemic Agreement remains purely theoretical. If a novel pathogen with pandemic potential were to emerge today, the international community would be forced to rely on the same fragmented, ad-hoc systems that failed so spectacularly during the last crisis.[3]